Larvol Delta - Bimekizumab-Demonstrated-Maintenance-of-Clinical-Efficacy-Responses-to-3-Years-in-Patients-with-Active-Psoriatic-Arthritis-from-Two-Phase-3-Studies

Bimzelx (bimekizumab-bkzx) - UCB

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1899168&mode=presInfo

Jessica Walsh, MD, MBA

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next